Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.

ABSTRACT:

Objective

Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de-identified medical records of 311 patients is the first real-world study examining persistence with liraglutide 3.0 mg in Canada, and also investigates associations between the SaxendaCare® patient support program and persistence and weight loss.

Methods

Overall persistence was assessed, as well as associations of enrollment in SaxendaCare®, persistence and weight loss.

Results

Overall mean (standard deviation) persistence with liraglutide 3.0 mg was 6.3 (4.1) months, and 67.5% (n = 210) and 53.7% (n = 167) of patients persisted for ≥4 and ≥ 6

SUBMITTER: Wharton S 

PROVIDER: S-EPMC7448157 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature